The latest market report published by Credence Research, Inc. “Global Bacterial Pneumonia Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2028”. The Global Bacterial Pneumonia Market generated revenue of around USD XX million in 2021 and is anticipated to grow a CAGR of over XX% during the forecast period from 2022 to 2028 to reach around USD XX million in 2028.
Because of the growth in bacterial resistance, antibiotics are becoming less effective in treating bacterial pneumonia. Pharmaceutical industry innovation is constantly focused on developing new kinds of antibiotics. It is believed that shortly, this will hasten the rate at which bacterial pneumonia is treated. Additionally, a significant factor in the market’s increase is the rise in the prevalence of community-acquired pneumonia, particularly in younger people. The procedures used by regulatory agencies to approve drugs for bacterial pneumonia have become more convoluted, generally impracticable, and possibly irrelevant to patients and physicians over time. Scientific and regulatory barriers also significantly raise the cost and length of drug development, which worsens the financial drawbacks of bacterial pneumonia treatments on the market.
Browse Global Bacterial Pneumonia Market report-https://www.credenceresearch.com/report/bacterial-pneumonia-market
The global Bacterial Pneumonia market is bifurcated into Disease Type, Drug Type, Dosage Form, Distribution Channel, and Geography. Based on disease type, the market is categorized into community-acquired pneumonia and healthcare-associated pneumonia. On the basis of drug type, the global market is segmented into antibiotics, cough medicine, pain killer/fever reducers, and vaccines. Based on dosage form, the market is categorized into oral and intravenous. On the basis of distribution channel, the global market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Based on geography, the market is segmented as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
North America controlled a significant portion of the market revenue in terms of value in 2021 and dominated the worldwide Bacterial Pneumonia market. Due to the burden of pneumonia infection and the increase in product approvals the region is growing the market. According to the Centers for Disease Control and Prevention, over 250,000 Americans undergo treatment for pneumonia each year, and 50,000 of them pass away as a result. Additionally, in 2019 the US FDA authorized Nabriva Therapeutics plc’s Xenleta for treating patients with community-acquired pneumonia. The market for pneumonia therapies is therefore expected to benefit from these factors.
Why to Buy This Report-
- The report provides a qualitative and quantitative analysis of the global Bacterial Pneumonia market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, base year- 2021, and forecast period 2022-2028.
- The report contains information related to the competitive landscape like how the key players in the market are operating at a global, regional, and country level
- In-depth analysis of the global bacterial pneumonia market segmentation based on disease type, drug type, dosage form, and distribution channel.
- The global Bacterial Pneumonia market report also includes analysing of the global, regional, and country level, along with key market trends, significant players analysis, market growth strategies, and key application areas.
The Global Bacterial Pneumonia Market is Segmented into:
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2016-2028 |
| Base Year | 2021 |
| Forecast Period | 2022 – 2028 |
| Historical Year | 2016 – 2021 |
| Unit | USD Billion |
| Segmentation | By Disease Type (2016–2028; US$ Bn) By Drug Type (2016–2028; US$ Bn) By Dosage Form (2016–2028; US$Bn) By Distribution Channel (2016–2028; US$Bn) By Geography Segment (2016–2028; US$Bn) |
